124 related articles for article (PubMed ID: 36765033)
1. Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.
Yu J; Yang K; Zheng J; Zhao P; Xia J; Sun X; Zhao W
Cell Death Dis; 2023 Feb; 14(2):101. PubMed ID: 36765033
[No Abstract] [Full Text] [Related]
2. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.
Yu J; Yang K; Zheng J; Zhao P; Xia J; Sun X; Zhao W
Cell Death Dis; 2022 Apr; 13(4):388. PubMed ID: 35449124
[TBL] [Abstract][Full Text] [Related]
3. Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway.
Yu JH; Zheng JB; Qi J; Yang K; Wu YH; Wang K; Wang CB; Sun XJ
Int J Oncol; 2019 Mar; 54(3):879-892. PubMed ID: 30747230
[TBL] [Abstract][Full Text] [Related]
4. Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2.
Zhou H; Ni Z; Li T; Su L; Zhang L; Liu N; Shi Y
Oncol Lett; 2018 May; 15(5):7617-7624. PubMed ID: 29849798
[TBL] [Abstract][Full Text] [Related]
5. Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand.
Yu J; Yang K; Zheng J; Zhao W; Sun X
Cancer Gene Ther; 2021 Jun; 28(6):590-601. PubMed ID: 33046820
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2).
Modica S; Cariello M; Morgano A; Gross I; Vegliante MC; Murzilli S; Salvatore L; Freund JN; Sabbà C; Moschetta A
J Biol Chem; 2014 Oct; 289(41):28421-32. PubMed ID: 25138215
[TBL] [Abstract][Full Text] [Related]
7. Expression and significance of CDX2, FXR, and TGR5 in esophageal cancer.
Zhang H; Qu X; Wang N; Zhang L; Yuan T; Shi M; Sun N; Yuan D; Ning H; Zhao M; Wang Y; Ni Z; Han C; Shi Y
Int J Clin Exp Pathol; 2022; 15(9):354-363. PubMed ID: 36237638
[TBL] [Abstract][Full Text] [Related]
8. Bile acids induce cdx2 expression through the farnesoid x receptor in gastric epithelial cells.
Xu Y; Watanabe T; Tanigawa T; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Oshitani N; Arakawa T
J Clin Biochem Nutr; 2010 Jan; 46(1):81-6. PubMed ID: 20104269
[TBL] [Abstract][Full Text] [Related]
9. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.
Matsuzaki J; Suzuki H; Tsugawa H; Watanabe M; Hossain S; Arai E; Saito Y; Sekine S; Akaike T; Kanai Y; Mukaisho K; Auwerx J; Hibi T
Gastroenterology; 2013 Dec; 145(6):1300-11. PubMed ID: 23933602
[TBL] [Abstract][Full Text] [Related]
10. Bile acids increase intestinal marker expression via the FXR/SNAI2/miR-1 axis in the stomach.
Wang N; Wu S; Zhao J; Chen M; Zeng J; Lu G; Wang J; Zhang J; Liu J; Shi Y
Cell Oncol (Dordr); 2021 Oct; 44(5):1119-1131. PubMed ID: 34510400
[TBL] [Abstract][Full Text] [Related]
11. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer.
Yin Y; Wang M; Gu W; Chen L
Biochem Pharmacol; 2021 Apr; 186():114430. PubMed ID: 33556338
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X receptor signal is involved in deoxycholic acid-induced intestinal metaplasia of normal human gastric epithelial cells.
Li S; Chen X; Zhou L; Wang BM
Oncol Rep; 2015 Nov; 34(5):2674-82. PubMed ID: 26324224
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5.
Hotta M; Sakatani T; Ishino K; Wada R; Kudo M; Yokoyama Y; Yamada T; Yoshida H; Naito Z
Biochem Biophys Res Commun; 2019 Nov; 519(4):824-831. PubMed ID: 31561852
[TBL] [Abstract][Full Text] [Related]
14. NRF2 and FXR dual signaling pathways cooperatively regulate the effects of oleanolic acid on cholestatic liver injury.
Liu J; Liu J; Meng C; Gu Q; Huang C; Liu F; Xia C
Phytomedicine; 2023 Jan; 108():154529. PubMed ID: 36343550
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor functions in cervical cancer via the p14
Huang X; Wang B; Shen H; Huang D; Shi G
Mol Biol Rep; 2022 May; 49(5):3617-3625. PubMed ID: 35347542
[TBL] [Abstract][Full Text] [Related]
16. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
17. Pioneer factor Foxa2 enables ligand-dependent activation of type II nuclear receptors FXR and LXRα.
Kain J; Wei X; Reddy NA; Price AJ; Woods C; Bochkis IM
Mol Metab; 2021 Nov; 53():101291. PubMed ID: 34246806
[TBL] [Abstract][Full Text] [Related]
18. Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis.
Miyazaki T; Shirakami Y; Mizutani T; Maruta A; Ideta T; Kubota M; Sakai H; Ibuka T; Genovese S; Fiorito S; Taddeo VA; Epifano F; Tanaka T; Shimizu M
Sci Rep; 2021 Jan; 11(1):492. PubMed ID: 33436792
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.
Peng Z; Chen J; Drachenberg CB; Raufman JP; Xie G
J Biol Chem; 2019 May; 294(21):8529-8542. PubMed ID: 30967475
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.
Yu J; Li S; Guo J; Xu Z; Zheng J; Sun X
Cell Death Dis; 2020 Aug; 11(8):640. PubMed ID: 32807788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
